Business Context and Reporting Period
This Form 8-K is a current report filed by Hancock Jaffe Laboratories, Inc. (not Envveno Medical Corp) on August 12, 2021. The registrant is a Delaware corporation with principal executive offices in Irvine, California. The report details the entry into a material definitive agreement regarding an equity financing program.
Key Financial Metrics and Transaction Details
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, or margins. The primary financial data relates to the new financing agreement:
- Offering Type: At-the-Market (ATM) Equity Offering.
- Maximum Proceeds: Up to $25,000,000 of common stock.
- Agent: Ladenburg Thalmann & Co. Inc.
- Commission Rate: Fixed at 3% of gross proceeds.
- Trading Symbols: Common Stock (HJLI) and Warrants (HJLIW) on the NASDAQ Capital Market.
Material Changes
The material change reported is the execution of the ATM Offering Agreement on August 12, 2021. This agreement authorizes the company to sell shares from time to time through the agent. The company retains the right to suspend or terminate the agreement at any time. The offering is scheduled to terminate on the earlier of August 12, 2023, or upon termination of the agreement.
Guidance, Outlook, and Risks
The filing does not contain specific financial guidance, management commentary on future performance, or a discussion of general business risks. The primary contingency noted is that the company has no obligation to sell any shares under the agreement. The offering relies on a previously filed Registration Statement on Form S-3 (File No. 333-237592) declared effective on April 16, 2020.
Investor Verification Checklist
- Verify the company name is Hancock Jaffe Laboratories, Inc. (HJLI), as the input metadata incorrectly referenced "Envveno Medical Corp."
- Confirm the 3% commission fee structure with the sales agent, Ladenburg Thalmann & Co. Inc.
- Review the attached Exhibit 10.1 (At-the-Market Offering Agreement) for specific terms regarding share pricing and suspension rights.
- Check the status of the underlying Form S-3 Registration Statement (File No. 333-237592) to ensure it remains effective for future sales.
- Note that this filing does not disclose current liquidity levels or debt obligations; refer to the most recent 10-K or 10-Q for those metrics.